Journal Article

Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study

Waltl, Eva E, Amoloja, Theresa, Xue, Zhenyi, Fleury, Isabelle, Koch, Caroline, Nowakowski, Grzegorz S, Dabas, Rosy, Peters, Anthea

2025

Overview

Abstract Background In the current Canadian treatment landscape for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL), eligibility for autologous stem cell transplantation (ASCT) guides the choice of salvage treatment. CD19 chimeric antigen receptor T-cell (CAR-T) therapies have improved outcomes in patients with chemorefractory DLBCL, but access is limited to eligible patients. This subanalysis of the RE-MIND2 observational retrospective cohort study investigated treatment patterns for R/R DLBCL in Canada. Patients and methods Data from patients enrolled in RE-MIND2 treated between 2010 and 2020 at 2 Canadian centers were retrospectively collected from health records. Descriptive statistics were used to analyze baseline characteristics, treatment initiated, and duration of treatment by line of therapy. Results One hundred and nine patients were included; 74.2% of patients were eligible for ASCT as 2L therapy, and 45.4% received transplants. ASCT eligibility for third- (3L) and fourth-line (4L) therapy declined to 17.1% and 5.9%, respectively. Patients received a wide variety of treatments in 3 and 4L. CAR-T therapy became available in 3 and 4L by the end of 2019. Median durations of treatment were <2.6 months in all lines of therapy; median time to next treatment ranged from 3.4 months in 4L to 5.3 months in 2L. Conclusion Results of our study support that ASCT-ineligible patients have a poor prognosis with conventional salvage chemotherapy. Before the availability of novel immunotherapies, no apparent standard of care was observed for Canadian patients with R/R DLBCL who were ineligible for or did not receive ASCT, especially after 2L treatment.

• Publisher: Oxford University Press
• Subject: Adult / Aged / Bendamustine / Canada / Cancer / Care and treatment / Chemotherapy / Development and progression / Female / Humans / Immunotherapy, Adoptive - methods / Lymphoma, Large B-Cell, Diffuse - pathology / Lymphoma, Large B-Cell, Diffuse - therapy / Male / Medical records / Medical research / Medicine, Experimental / Middle Aged / Neoplasm Recurrence, Local - pathology / Neoplasm Recurrence, Local - therapy / Non-Hodgkin's lymphomas / Prognosis / Relapse / Retrospective Studies / Salvage Therapy - methods / Stem cells / T cells / Transplantation / Vincristine